Cisplatin-Mediated Upregulation of APE2 Binding to MYH9 Provokes Mitochondrial Fragmentation and Acute Kidney Injury

These results reveal and highlight an unexpected role of APE2 via its interaction with MYH9 and suggest that APE2 has the potential to prevent acute kidney injury in cisplatin-treated cancer patients. Cisplatin chemotherapy is standard care for many cancers but is toxic to the kidneys. How this toxicity occurs is uncertain. In this study, we identified apurinic/apyrimidinic endonuclease 2 (APE2) as a critical molecule upregulated in the proximal tubule cells (PTC) following cisplatin-induced nuclear DNA and mitochondrial DNA damage in cisplatin-treated C57B6J mice. The APE2 transgenic mouse phenotype recapitulated the pathophysiological features of C-AKI (acute kidney injury, AKI) in the absence of cisplatin treatment. APE2 pulldown-MS analysis revealed that APE2 binds myosin heavy-Chain 9 (MYH9) protein in mitochondria after cisplatin treatment. Human MYH9-related disorder is caused by mutations in MYH9 that eventually lead to nephritis, macrothrombocytopenia, and deafness, a constellation of symptoms similar to the toxicity profile of cisplatin. Moreover, cisplatin-induced C-AKI was attenuated in APE2-knockout mice. Taken together, these findings suggest that cisplatin promotes AKI development by upregulating APE2, which leads to subsequent MYH9 dysfunction in PTC mitochondria due to an unrelated role of APE2 in DNA damage repair. This postulated mechanism and the availability of an engineered transgenic mouse model based on the mechanism of C-AKI provides an opportunity to identify novel targets for prophylactic treatment of this serious disease. Significance: These results reveal and highlight an unexpected role of APE2 via its interaction with MYH9 and suggest that APE2 has the potential to prevent acute kidney injury in patients with cisplatin-treated cancer. Graphical Abstract: http://cancerres.aacrjournals.org/content/canres/81/3/713/F1.large.jpg. Graphical Abstract

[1]  Ira Milosevic,et al.  Mitochondrial fission requires DRP1 but not dynamins , 2019, Nature.

[2]  M. Perše,et al.  Cisplatin-Induced Rodent Model of Kidney Injury: Characteristics and Challenges , 2018, BioMed research international.

[3]  Jian-jun Zhao,et al.  Targeting the MALAT1/PARP1/LIG3 complex induces DNA damage and apoptosis in multiple myeloma , 2018, Leukemia.

[4]  Md Akram Hossain,et al.  APE2 promotes DNA damage response pathway from a single-strand break , 2018, Nucleic acids research.

[5]  K. Surendran,et al.  Nonmuscle myosin 2 proteins encoded by Myh9, Myh10, and Myh14 are uniquely distributed in the tubular segments of murine kidney , 2017, Physiological reports.

[6]  P. Bhargava,et al.  Mitochondrial energetics in the kidney , 2017, Nature Reviews Nephrology.

[7]  Leah J. Siskind,et al.  Developing better mouse models to study cisplatin-induced kidney injury. , 2017, American journal of physiology. Renal physiology.

[8]  A. Prakash,et al.  DNA damage related crosstalk between the nucleus and mitochondria. , 2017, Free radical biology & medicine.

[9]  H. Higgs,et al.  Novel roles for actin in mitochondrial fission , 2014, Journal of Cell Science.

[10]  C. Edelstein,et al.  Pathophysiology of Cisplatin-Induced Acute Kidney Injury , 2014, BioMed research international.

[11]  C. E. Schrader,et al.  Differential expression of APE1 and APE2 in germinal centers promotes error-prone repair and A:T mutations during somatic hypermutation , 2014, Proceedings of the National Academy of Sciences.

[12]  R. Adelstein,et al.  The role of vertebrate nonmuscle Myosin II in development and human disease , 2014, Bioarchitecture.

[13]  H. Higgs,et al.  A Role for Myosin II in Mammalian Mitochondrial Fission , 2014, Current Biology.

[14]  S. Ledoux,et al.  The maintenance of mitochondrial DNA integrity--critical analysis and update. , 2013, Cold Spring Harbor perspectives in biology.

[15]  S. D. Cline.  Mitochondrial DNA damage and its consequences for mitochondrial gene expression. , 2012, Biochimica et biophysica acta.

[16]  L. Holzman,et al.  Podocyte-Specific Deletion of Myh9 Encoding Nonmuscle Myosin Heavy Chain 2A Predisposes Mice to Glomerulopathy , 2011, Molecular and Cellular Biology.

[17]  J. Walker,et al.  Actin and myosin contribute to mammalian mitochondrial DNA maintenance , 2011, Nucleic acids research.

[18]  C. E. Schrader,et al.  Apurinic/Apyrimidinic Endonuclease 2 Is Necessary for Normal B Cell Development and Recovery of Lymphoid Progenitors after Chemotherapeutic Challenge , 2011, The Journal of Immunology.

[19]  S. Kawamoto,et al.  Ablation of Nonmuscle Myosin II-B and II-C Reveals a Role for Nonmuscle Myosin II in Cardiac Myocyte Karyokinesis , 2010, Molecular biology of the cell.

[20]  S. Rosset,et al.  Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene , 2010, Human Genetics.

[21]  L. Haracska,et al.  Role of PCNA-dependent stimulation of 3′-phosphodiesterase and 3′–5′ exonuclease activities of human Ape2 in repair of oxidative DNA damage , 2009, Nucleic acids research.

[22]  P. Noris,et al.  Position of nonmuscle myosin heavy chain IIA (NMMHC‐IIA) mutations predicts the natural history of MYH9‐related disease , 2008, Human mutation.

[23]  T. Jacks,et al.  Restoration of p53 function leads to tumour regression in vivo , 2007, Nature.

[24]  Z. Dong,et al.  Differential Gender Differences in Ischemic and Nephrotoxic Acute Renal Failure , 2005, American Journal of Nephrology.

[25]  M. Ohno,et al.  Growth retardation and dyslymphopoiesis accompanied by G2/M arrest in APEX2-null mice. , 2004, Blood.

[26]  T. Boulikas,et al.  Cisplatin and platinum drugs at the molecular level. (Review). , 2003, Oncology reports.

[27]  Anne M. Galea,et al.  The interaction of cisplatin and analogues with DNA in reconstituted chromatin. , 2002, Biochimica et biophysica acta.

[28]  J. White,et al.  Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromes. , 2001, American journal of human genetics.

[29]  K. Sakumi,et al.  Human APE2 protein is mostly localized in the nuclei and to some extent in the mitochondria, while nuclear APE2 is partly associated with proliferating cell nuclear antigen. , 2001, Nucleic acids research.

[30]  R. Safirstein,et al.  Uptake and metabolism of cisplatin by rat kidney. , 1984, Kidney international.

[31]  M. Weiner,et al.  Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations. , 1980, The Journal of pharmacology and experimental therapeutics.

[32]  T. Ninomiya,et al.  Direct involvement of the receptor-mediated apoptotic pathways in cisplatin-induced renal tubular cell death. , 2003, Kidney international.

[33]  Y. Iwamoto,et al.  Characterization of the genomic structure and expression of the mouse Apex2 gene. , 2003, Genomics.